AB | BC | MB | NB | NL | NS | NT | ON | PE | QC | SK | YT

News & Announcements

2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008

May | Apr | Mar | Feb | Jan

Health Product Risk Communication
May 16, 2016

SGLT2 Inhibitors [INVOKANA (canagliflozin), FORXIGA (dapagliflozin), XIGDUO (dapagliflozin/metformin), JARDIANCE (empagliflozin)] - Risk of Diabetic Ketoacidosis - Janssen Inc., Boehringer Ingelheim (Canada) Ltd.

Serious, sometimes life-threatening and fatal cases of diabetic ketoacidosis (DKA) have been reported in patients on sodium glucose co-transporter 2 (SGLT2) inhibitors for type 1 and type 2 diabetes. In a number of these cases, the presentation of the condition was atypical with only moderately increased blood glucose levels observed. SGLT2 inhibitors are NOT indicated for treatment of type 1 diabetes mellitus and should not be used in type 1 diabetes.

Health Canada Health Product Risk Communication

Information Update
May 13, 2016

Health Canada warns Canadians not to use unauthorized ‘LifeGive’ health products with misleading health claims

Health Canada is warning Canadians not to purchase or use ‘LifeGive’ health products to treat diseases such as cancer and dementia. These products are not authorized for sale in Canada.  Health Canada believes ‘LifeGive’ health products have been or will be promoted by Hippocrates Health Institute at several events held at locations in Ontario this month.

Health Canada Information Update

Information Update
May 10, 2016

Health Canada is informing Canadians of risks related to certain preservatives in cosmetic, non-prescription and natural health products

Health Canada is informing consumers of potential risks related to the combination of methylisothiazolinone and methylchloroisothiazolinone (MI/MCI) used as a preservative in certain leave-on cosmetic, non-prescription and natural health products.

Health Canada Information Update

Health Product Risk Communication
May 18, 2016

BICILLIN L-A Injection (penicillin G benzathine) 2 mL Single Use Syringe - Shortage and Replacement with Australian Labelled Stock - Pfizer Canada Inc.

During the temporary supply disruption of BICILLIN L-A (penicillin G benzathine) in Canada, Health Canada has facilitated the importation of Pfizer Australian labelled BICILLIN L-A, lot 72453, which is the same as the Canadian product. Although the Australian BICILLIN L-A product is being used, the BICILLIN L-A Canadian Product Monograph should be referred to for information.

Health Canada Health Product Risk Communication

Health Product Risk Communication
May 04, 2016

BCR-ABL Tyrosine Kinase Inhibitors [GLEEVEC (imatinib mesylate), TASIGNA (nilotinib), BOSULIF (bosutinib), SPRYCEL (dasatinib), ICLUSIG (ponatinib hydrochloride)] - Risk of Hepatitis B Reactivation - Novartis Pharmaceuticals Canada Inc., Pfizer Canada Inc. Canada, Bristol-Myers Squibb, ARIAD Pharmaceuticals, Inc.

Cases of reactivation of hepatitis B virus (HBV) have occurred in patients who are chronic carriers of HBV after they received BCR-ABL tyrosine kinase inhibitors. Some cases of HBV reactivation resulted in acute hepatic failure or fulminant hepatitis leading to liver transplantation or a fatal outcome.

Health Canada Health Product Risk Communication

Health Product Risk Communication
May 03, 2016

ZYDELIG (idelalisib) - Increased Risk of Fatal and Serious Infections - Gilead Sciences Canada, Inc.

Decreased overall survival and an increased risk of serious adverse events (mostly infections) were observed in patients receiving ZYDELIG compared to the control groups in clinical trials.

Health Product Risk Communication

Advisory
May 02, 2016

Unauthorized products seized at Calgary retailer may pose serious health risks

Health Canada seized seventeen unauthorized health products from the retailer, Matrioshka Russian Delicatessen, in Calgary, Alberta. Two unauthorized products were labelled with prescription drug ingredients (captopril and sulfanilamide). Products that contain prescription drug ingredients should only be taken under the supervision of a health professional because they are used to treat specific diseases, and may cause serious side effects.

Health Canada Advisory

Health Product Risk Communication
May 02, 2016

Cook Catheters with Beacon Tip Technology – Recall Due to Degradation of Catheter Tip - Cook (Canada) Inc.

Cook Catheters with Beacon Tip technology have been recalled due to polymer degradation of the catheter tip, which could result in tip fracture and/or separation. Health Canada is aware that this may cause a shortage issue. To obtain information on other products that can be used as alternatives, healthcare professionals should contact Cook Medical directly.

Health Canada Health Product Risk Communication

Advisory
May 24, 2016

Unauthorized product, Animal Test, seized from Supplement King in Burlington may pose serious risk to health

Health Canada seized an unauthorized product being promoted as a dietary supplement, Animal Test, from Supplement King, 1250 Brant Street, Unit 9a, Burlington, Ontario. This product contains yohimbine, a prescription drug ingredient.

Health Canada Advisory

Health Product InfoWatch - April 2016
May 02, 2016

The April issue of the Health Product InfoWatch published by Health Canada is now available.
[> More]